Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 181Breast Neoplasms 154Prostatic Neoplasms 144Lung Neoplasms 139Glioblastoma 119Head and Neck Neoplasms 115Squamous Cell Carcinoma of Head and Neck 110Rectal Neoplasms 107Lymphoma 101Esophageal Neoplasms 100Pancreatic Neoplasms 76Esophageal Squamous Cell Carcinoma 71Leukemia 70Neoplasms 67Brain Neoplasms 67Lymphoma, Follicular 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Lymphoma, Non-Hodgkin 62Lymphoma, Large B-Cell, Diffuse 58Hodgkin Disease 56Uterine Cervical Neoplasms 53Central Nervous System Neoplasms 53Leukemia, Lymphocytic, Chronic, B-Cell 52Gliosarcoma 51Sarcoma 50Colorectal Neoplasms 50Neoplasm Metastasis 45Lymphoma, Large-Cell, Immunoblastic 45Glioma 44Burkitt Lymphoma 43

Interventions

tislelizumab 1nedaplatin 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Immunotherapy Esophagus Cancer × Radiotherapy × Clear all
NCT05515315 2024-02-07

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

Fuzhou General Hospital

Phase 2 Recruiting
93 enrolled
Gastrointestinal

Immunotherapy Esophagus Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡